Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

In our study, anti–CTLA-4 therapy was not associated with a significantly increased risk of GI adverse events compared with anti–PD-1/PD-L1 therapy; however, this association was significant in the univariable analysis and showed a tendency toward significance in the multivariable analysis.

also in 340 other papers